All In Biotech

Drug Trial Radar · NCT03029208

Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis (ASCEND-ID)

A 52-week Open-label (Sponsor-blind), Randomized, Active-controlled, Parallel-group, Multi-center Study to Evaluate the Efficacy and Safety of Daprodustat Compared to Recombinant Human Erythropoietin in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Initiating Dialysis

Last checked: Nov 19, 2026Latest source record: Oct 20, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 312 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

312

Actual

Start

May 11, 2017

Primary completion

Sep 24, 2020

Study completion Sep 24, 2020

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Jan 24, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this multi-center study is to evaluate the efficacy and safety of daprodustat in subjects with anemia associated with CKD.

Conditions

  • Anaemia

Interventions

  • DaprodustatDrug

    Daprodustat will be supplied as film coated tablets for oral administration containing 1, 2, 4, 6, 8, or 10 mg of daprodustat. Doses of 12, 16, and 24 mg of daprodustat will be provided using multiples of these tablet strengths.

  • Darbepoetin alfaDrug

    Darbepoetin alfa will be supplied as prefilled syringes (PFS) for SC/IV injection available in strengths: 20, 30, 40, 60, 80, 100 and 150 mcg.

  • Iron therapyDrug

    Iron therapy will be administered if ferritin is \<=100 ng/mL and/or TSAT is \<=20%.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change From Baseline in Hemoglobin (Hgb) During Evaluation Period (Week 28 to Week 52)Time frame: Baseline (Pre-dose on Day 1) and evaluation period (Week 28 to Week 52)

Locations

111 sites in 15 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Anaheim, California

  • GSK Investigational Site

    Cerritos, California

  • GSK Investigational Site

    Escondido, California

  • GSK Investigational Site

    Glendale, California

  • GSK Investigational Site

    La Palma, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Lynwood, California

  • GSK Investigational Site

    Sacramento, California

  • GSK Investigational Site

    Whittier, California

  • GSK Investigational Site

    Middlebury, Connecticut

  • GSK Investigational Site

    Coral Gables, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Augusta, Georgia

  • GSK Investigational Site

    Chicago, Illinois

  • GSK Investigational Site

    Crystal Lake, Illinois

  • GSK Investigational Site

    Fort Wayne, Indiana

  • GSK Investigational Site

    Merrillville, Indiana

  • GSK Investigational Site

    Michigan City, Indiana

  • GSK Investigational Site

    Iowa City, Iowa

  • GSK Investigational Site

    Baton Rouge, Louisiana

  • GSK Investigational Site

    New Orleans, Louisiana

  • GSK Investigational Site

    Baltimore, Maryland

  • GSK Investigational Site

    Jackson, Mississippi

  • GSK Investigational Site

    Kansas City, Missouri

  • GSK Investigational Site

    St Louis, Missouri

  • GSK Investigational Site

    Brooklyn, New York

  • GSK Investigational Site

    Buffalo, New York

  • GSK Investigational Site

    Mineola, New York

  • GSK Investigational Site

    New York, New York

  • GSK Investigational Site

    The Bronx, New York

  • GSK Investigational Site

    Houston, Texas

  • GSK Investigational Site

    Lufkin, Texas

  • GSK Investigational Site

    San Antonio, Texas

  • GSK Investigational Site

    Hampton, Virginia

  • GSK Investigational Site

    Buenos Aires, Argentina

  • GSK Investigational Site

    Formosa, Argentina

  • GSK Investigational Site

    Mendoza, Argentina

  • GSK Investigational Site

    San Miguel de Tucumán, Argentina

Showing 40 of 111 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.